# Envollizumab Combined With Fruquintinib and SOX Versus SOX for Conversion Therapy in Advanced Gastric Cancer

> **NCT05914610** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Fujian Medical University** · enrollment: 100 (estimated)

## Conditions studied

- Gastric Cancer

## Interventions

- **DRUG:** Envolimab
- **DRUG:** Fruquintinib
- **DRUG:** Oxaliplatin
- **DRUG:** Tegafur

## Key facts

- **NCT ID:** NCT05914610
- **Lead sponsor:** Fujian Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2023-09-01
- **Primary completion:** 2025-07-30
- **Final completion:** 2028-07-30
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2023-08-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05914610

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05914610, "Envollizumab Combined With Fruquintinib and SOX Versus SOX for Conversion Therapy in Advanced Gastric Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05914610. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*